AMPH
Quality Rating
Amphastar Pharmaceuticals, Inc. (AMPH) is a biopharmaceutical company specializing in generic and proprietary injectable products, operating primarily in the healthcare sector. While its core business activities align with Shariah principles by providing essential medications without involvement in prohibited industries, the company's financial metrics, particularly a high debt ratio of 50.93%, result in non-compliance under major Shariah screening standards. Index inclusion research confirms exclusion from all major Shariah-compliant indices due to these financial thresholds. Purification is required for minor interest income, and ESG factors show low risk with no significant controversies impacting compliance. Overall, AMPH presents opportunities in permissible healthcare but requires caution due to leverage concerns.
Purification Required
Moderate purification required - consider carefully
Index Inclusion
Excluded from S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, and Dow Jones Islamic Market (DJIM)
Key Compliance Considerations
- Debt Ratio: 50.93% exceeds thresholds across AAOIFI (30%), MSCI (33.33%), and S&P (33%) standards
- Persistent high leverage may indicate ongoing riba exposure in financing structure
Debt Ratio
50.9%
Liquidity Ratio
18.5%
Interest Income Ratio
2.3%
Purification
2.33%